Amgen’s R&D efforts comprise of four guiding principles. The first is to focus on developing therapies that have a beneficial effect on patients suffering from the greatest unmet medical needs. Amgen’s R&D programs aim to help patients in the following therapeutic areas: haematology, oncology, inflammation, neurology and metabolic disorders.
The second is to be modality independent - to fit the tool for task. For us the question is always: What’s the best therapeutic approach for a particular disease?
The third is to study disease in patients, as experimental models can have little predictive value with respect to human disease.
The final guiding principle is seamless integration: integrating Amgen’s organisation, incorporating the perspectives from sales and marketing, clinical development and basic research into all of its drug development programs. Aligning our priorities across these functions ensures the development of potential therapeutics in a manner that will address unmet medical needs and meet the changing demands of the marketplace.
These four guiding principles together are not enough to ensure our success as an organisation. Hard work, intelligence, intuition, and some luck, are also essential.
